Provided by Tiger Trade Technology Pte. Ltd.

RenovoRx Inc

0.9700
-0.0200-2.02%
Volume:69.05K
Turnover:67.48K
Market Cap:35.55M
PE:-2.73
High:0.9999
Open:0.9736
Low:0.9600
Close:0.9900
52wk High:1.45
52wk Low:0.7006
Shares:36.65M
Float Shares:30.09M
Volume Ratio:0.38
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3554
EPS(LYR):-0.3958
ROE:-146.61%
ROA:-68.39%
PB:4.40
PE(LYR):-2.45

Loading ...

Company Profile

Company Name:
RenovoRx Inc
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
10
Office Location:
2570 West El Camino Real,Suite 320,Mountain View,California,United States
Zip Code:
94040
Fax:
650 397 4433
Introduction:
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Directors

Name
Position
Ramtin Agah
Chief Medical Officer and Chairman of the Board
Shaun R. Bagai
Chief Executive Officer and Director
Kristen Angela Macfarlane
Director
Laurence J. Marton
Director
Robert Spiegel
Director
Una S. Ryan
Director

Shareholders

Name
Position
Shaun R. Bagai
Chief Executive Officer and Director
Mark Voll
Chief Financial Officer
Leesa Gentry
Chief Clinical Officer
Ramtin Agah
Chief Medical Officer and Chairman of the Board
Ronald B. Kocak
Vice President and Controller